WASHINGTON, Dec. 11, 2012 /PRNewswire-USNewswire/ --The Personalized Medicine Coalition (PMC) today announced that Julie K. Goonewardene was elected to the Coalition's board of directors for a three-year term beginning November 27, 2012.

(Photo: http://photos.prnewswire.com/prnh/20121211/DC27601)

"Our success in promoting personalized medicine is largely driven by our dedicated and engaged membership as well as an active board. Based on her dedication to moving science from the bench to the bedside, Julie can assist us in advocating for pro-innovation policies that will help patients and improve health care," said William S. Dalton, Ph.D., M.D., CEO M2Gen, director Personalized Medicine Institute at Moffitt Cancer Center, and vice chairman of the PMC.

Ms. Goonewardene currently serves as the public member of the American Medical Association (AMA) Board of Trustees, and her nomination to serve on the PMC board was supported by James L. Madara, M.D., Executive Vice President and CEO of the AMA. The AMA is the largest association of physicians and medical students in the United States. Its mission is to promote the art and science of medicine and the betterment of the public health.

"We are pleased that Julie is joining the PMC board and believe her extensive background and expertise in business and health care issues, particularly in the realm of bringing cutting-edge medical research to the bedsides of patients, will serve the PMC board well," said Dr. Madara.

In addition to serving in her current role as an AMA board member, Ms. Goonewardene is the Associate Vice Chancellor for Innovation and Entrepreneurship at the University of Kansas (KU), president of the KU Center for Technology Commercialization and a professor of practice in the KU School of Business. Prior to KU, she held various roles at Purdue University. She is an experienced entrepreneur, an author, and frequent speaker on innovation. She earned a B.S with Honors in Management and a Masters in Health Communication from Purdue University.

"I am honored to join the PMC board and work with its exceptional team," Goonewardene said. "PMC has been a leader across the personalized medicine landscape for nearly a decade. I look forward to sharing my experiences and contributing to the development and adoption of personalized medicine."

About the Personalized Medicine Coalition: The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit http://www.PersonalizedMedicineCoalition.org.

Contact:Tiffany Harrington, Director, Public Affairs tharrington@PersonalizedMedicineCoalition.org (202) 589-1755

SOURCE Personalized Medicine Coalition

View original post here:

Personalized Medicine Coalition Elects New Board Member

HOUSTON, TX--(Marketwire - Dec 11, 2012) - Dr. Mark Sanders joins an elite group of orthopedic and sports medicine specialists as he accepts membership into the American Orthopaedic Society for Sports Medicine (AOSSM).

A board-certified orthopedic surgeon and founder of the Sanders Clinic for Orthopaedic Surgery and Sports Medicine, Dr. Sanders' membership comes on the heels of his recently published study in the Journal of Sports Medicine -- Knee Injuries and the Use of Prophylactic Knee Bracing in Off-Road Motorcycling -- and his ongoing research of ACL injuries and reconstructions.

With a subspecialty certificate in orthopaedic sports medicine, Dr. Sanders has dedicated the greater part of his 32-year career caring for the extreme athlete.Today he is chief of staff at the North Texas Medical Center in Gainesville and on staff at Doctors Hospital Tidwell, and Victory Medical Center of Houston.

According to Dr. Sanders, the membership is a natural extension of his work and dedication to research in orthopedics and sports medicine.

"I am honored to sit among physicians contributing to better healthcare and treatment plans -- with the common goal to improve the outcome and quality of life for patients," said Dr. Sanders.

"The number of patients we see for repair of their failed total knee replacements and other procedures that leave them with less than optimal results is a testament to the work we're doing," added Sanders.

Dr. Sanders is also applying his "back to the basics" approach in addressing foot and ankle conditions, such as bunions and adult acquired flat foot deformity (AAFFD), to yield better outcomes than those reported from more invasive procedures.

Dr. Sanders is a fellow of the American Academy of Orthopaedic Surgeons (AAOS) and the American College of Surgeons.He is also a member of the American Orthopaedic Foot & Ankle Society (AOFAS) and the American Board of Orthopaedic Surgery (ABOS).

AOSSM was developed to provide a scientific outlet for presentation and publication of new ideas, as well as provide an opportunity for physicians to meet and exchange ideas on research, clinical problems, proposals for future progress in sports medicine and a high level publication controlled by the Society. This vision has expanded today to also foster international collaboration and communication among members world-wide.

He has a subspecialty in orthopedic sports medicine and is best known for his no nonsense approach to recovery -- getting his patients up on their feet and back to limb building movement immediately after a procedure.

Link:

Houston Orthopedic and Sports Medicine Specialist Mark Sanders, M.D., Inducted Into the American Orthopaedic Society ...

WALTHAM, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has obtained a CE Mark enabling the commercial sale of the CardioSCORE(TM) test in the EU and other countries that recognize the CE Mark. The CardioSCORE test is the company's patented diagnostic blood test designed to dramatically improve risk prediction of major cardiovascular events beyond traditional risk factor assessments, such as the Framingham Risk Score and European SCORE.

The CardioSCORE test is performed on a standard blood sample and utilizes algorithmic analysis to combine the results of seven reimbursed protein assays. The test involves an independent scoring system that yields a quantitative result ranging from 0.0 to 10.0, with higher values indicating elevated risk for a major cardiovascular event in the subsequent 3 years and with each 1.0 point increment representing a 30% increase in relative risk. In the 6,600 patient BioImage Study cohort, the primary clinical validation study for the CardioSCORE test, among those who experienced a near-term major cardiovascular event during follow-up, only 26% were identified as being at high risk at baseline by traditional risk factors, whereas 54% percent were identified as being at high risk upon addition of their CardioSCORE result (p<0.0001).

"We are thrilled to bring the benefits of the CardioSCORE test to patients and physicians in Europe. We believe this test will be a pivotal and disruptive game-changer in the primary prevention of major cardiovascular events and treatment of disease, representing a major advancement over the diagnostic tools clinicians have used for the past 15 years," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. "The majority of cardiovascular events occur among patients who are asymptomatic, and current risk factor assessment methods simply miss too many patients with hidden subclinical risk, delaying appropriate therapy and effective monitoring of response to such therapy. The CardioSCORE test will identify individuals at elevated risk for heart attack and stroke, enabling preventive intervention. We are working aggressively to launch the test in the first half of 2013 in Europe in collaboration with specialty laboratory partners."

"The CardioSCORE test may have the potential to help improve the care of many people by providing a simple, accurate and clinically meaningful score to assess an individual's risk for near-term major cardiovascular events," said Valentin Fuster, MD, PhD, Professor of Cardiology and Director of Mount Sinai Heart.

Last month, investigators at the American Heart Association (AHA) Scientific Sessions 2012 presented the results of several analyses of the CardioSCORE test performance in the BioImage Study. The presentations by investigators from the Mt. Sinai School of Medicine and the Baptist Hospital of Miami highlighted the predictive value of the test in assessing risk for near-term major cardiovascular events across a broad and diverse community-dwelling population. A summary of these findings is available here: http://investor.bg-medicine.com/releases.cfm.

"Obtaining the CE Mark for the CardioSCORE test is not only a significant milestone in the prevention and treatment of cardiovascular disease but also a critical advancement in our company's continued transformation into a full-scale commercial organization," continued Mr. Bouvier. "BG Medicine now has two products covering the continuum of heart disease diagnostics, positioning us strongly to drive the clinical usage of our important diagnostic tests for millions of patients who will benefit from them throughout the world."

The CardioSCORE test is not yet available commercially in the United States. BG Medicine is continuing its active discussions with the US Food and Drug Administration regarding 510(k) clearance for the test in the United States.

About BG Medicine, Inc.

BG Medicine, Inc. (BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company has two products: the BGM Galectin-3(R) test for use in patients with chronic heart failure is available in the United States and Europe; and the CardioSCORE(TM) test for the risk prediction of major cardiovascular events will be launched in Europe in the first half of 2013. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Continue reading here:

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

NEW YORK, Dec. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Regenerative Medicine Industry http://www.reportlinker.com/p090567/Global-Regenerative-Medicine-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

This report analyzes the worldwide markets for Regenerative Medicine in US$ million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 93 companies including many key and niche players such as BioVest International, Inc., Curis, Inc., Cytori Therapeutics, Inc., Evotec AG, Forticell Bioscience, Inc., Geron Corporation, Integra LifeSciences Corporation, LifeCell Corporation, Osiris Therapeutics, Inc., Tengion, Inc., Tepha Inc., and TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1 A Primer II-1 Current and Future Analysis II-1 Current Global Market for Regenerative Medicine II-2 Therapeutic Companies and Products in Regenerative Medicine - Current Status II-2 Select Therapeutic Regenerative Medicine Products in the Global Market II-3 Market Potential II-3

2. REGENERATIVE MEDICINE IN BONE AND JOINT APPLICATIONS II-5 An Overview of Regenerative Medicine in Bone and Joint Applications II-5 Bone Graft Substitutes - Penetration in Foot and Ankle Surgeries II-5 Repair of Non-Healing Bones - High Market Potential II-5 Market Potential of Bone Graft Substitutes (BGSs) II-6 Table 1: Global Bone Graft Substitute Market (2010): Percentage Share Breakdown of Sales for DePuy, OrthoVita, ApaTech/Baxter, Wright Medical, Medtronic/RTI, Biomet, and Others (includes corresponding Graph/Chart) II-6 Synthetic Bone Graft Substitutes to Replace Traditional Autografts and Allografts II-6 Select Synthetic Products in Orthobiologics II-7 Bone Morphogenic Proteins (BMPs) Gaining Popularity II-7 Bone Morphogenic Protein products in Orthobiology II-7 Table 2: Global Bone Morphogenic Protein Market (2010): Percentage Share Breakdown of Sales for Medtronic/RTI, and Stryker (includes corresponding Graph/Chart) II-7 Demineralized Bone Matrices (DBMs) Market Getting Crowded II-8 Table 3: Global Demineralized Bone Matrix Market (2011): Percentage Share Breakdown of Value Sales for Medtronic/RTI, Synthes/MTF, Integra LifeSciences, Altiva, Bacterin, and Others (includes corresponding Graph/Chart) II-8 Select DBM products in Orthobiologics market II-8 Biomaterials Market - Promising Opportunities for Cost- Effective Products II-8 Existing Bone Graft Procedures - Limitations and Concerns II-9 Autograft Procedures II-9 Allograft - DBM and Other Allografts II-9 BMPs and Other Synthetic Growth Factors II-9 Medical Devices and Implants for Orthopedics II-10 Expanding Opportunities in Hip and Knee Market II-10 Extremity Reconstruction - A Growing Market II-10 Tissue Engineered Cartilage Market - An Overview II-11 Tissue Engineered Cartilages - A Promising Solution for Cartilage Repair II-11 Market Potential of Tissue Engineered Cartilage Products II-11 Potential Applications of Tissue Engineered Cartilage Products II-11 Commercially Available tissue engineered cartilage products II-12 Challenges in Clinical Application of Tissue Engineered Cartilage Products II-13 Bone Marrow Transplants (BMTs) II-13 Market Potential for BMTs II-14 Companies Engaged in CBSC Research for BMTs II-14 Table 4: Global Orthobiologics Market (2010): Percentage Share Breakdown of Value Sales for Medtronic/RTI, Synthes/MTF, DePuy, Osteotech, Orthofix, and Others (includes corresponding Graph/Chart) II-14

Table 5: Global Orthobiologics Market (2010): Percentage Share Breakdown of Value Sales by Product Type for Growth Factors, Synthetics, DMBs, Allografts, and Stem Cells (includes corresponding Graph/Chart) II-15

Table 6: Global Machined Bone and Allograft Market (2010): Percentage Share Breakdown of Value Sales for Synthes/MTF, DePuy, Medtronic/RTI, Osteotech, RTIX, and Others (includes corresponding Graph/Chart) II-15

Table 7: Global Stem Cell Orthobiologics Market (2010): Percentage Share Breakdown of Value Sales for Nuvasive, and Otrhofix includes corresponding Graph/Chart) II-15

Originally posted here:

Global Regenerative Medicine Industry

Christopher Goerdt, MD, MPH
Dr Goerdt is a internal medicine physician at University of Iowa Hospitals and Clinics, Iowa City, Ia. "It is an honor and a privilege caring for my patients especially at the University of Iowa." C. GoerdtFrom:uihealthcareViews:0 0ratingsTime:01:20More inScience Technology

Read this article:

Christopher Goerdt, MD, MPH - Video

Nopal Cactus Health Benefits of the Nopal Cactus
Nopal Cactus Health Benefits - nopaljuicestore.com The nopal cactus is said to offer a ton of health benefits. The nopal cactus fruit is loaded with bioflavonoids that may help relieve inflammation. The Nopal cactus, or prickly pear, has been used since ancient times for food and medicinal purposes. Cultivated around the world, Nopal cactus is generally believed to be indigenous to North America, particularly Mexico. It is an important food source in Mexico and is such an integral part of their culture that it appears on the Mexican flag. Research unveiled that Nopal cactus fruit has anti-inflammatory and antioxidant properties, thanks to a class of rare and potent nutrients called bioflavonoids. Bioflavonoids are in the quercetin family, which have been shown to protect against inflammation related to free radicals (unstable molecules in the body). Nopal cactus fruit is a rich source of quercetin. Now, the power of the Nopal cactus fruit is available in Nopalea. It contains nutrients that are proven to help the body reduce inflammation, which may help reduce pain due to inflammation, improve joint health, relieve swelling muscles, protect cellular health and much more! Traditionally, Nopal cactus fruit was used by indigenous peoples as medicine for a variety of health conditions. More recently, scientific research has show that when eaten, the Nopal cactus fruit can help protect the immune and nervous systems and protect against oxidative stress.From:NopalJuiceStoreViews:0 0ratingsTime:01:59More inEducation

Read the original:

Nopal Cactus Health Benefits of the Nopal Cactus - Video

Rachael Dirksen, MD
Dr Dirksen is a internal medicine physician at University of Iowa Hospitals and Clinics, Iowa City, Ia. "I love internal medicine because it is a wonderful combination of humanism and science. I get to solve problems and improve the lives of my patients at the same time." R. DirksenFrom:uihealthcareViews:0 0ratingsTime:01:39More inScience Technology

See the original post:

Rachael Dirksen, MD - Video

Carilion Meningitis Nov 2012
Carilion Clinic #39;s Infectious Disease team authored the research article, "Early Clinical Observations in Prospectively Followed Patients With Fungal Meningitis Related to Contaminated Epidural Steroid Injections," in the Nov. 12, 2012, issue of the Annals of Internal Medicine. In this video, the authors offer additional insight into their original research article.From:CarilionClinicViews:4 0ratingsTime:04:40More inEducation

Original post:

Carilion Meningitis Nov 2012 - Video

The Importance of Holistic Lifestyle Change
Learn about Holistic Lifestyle Change from Kristine Soly MD, board certified in Internal Medicine, Cardiology, and Holistic Medicine. Learn more at http://www.drsoly.comFrom:Kristine SolyViews:0 0ratingsTime:04:40More inEducation

Here is the original post:

The Importance of Holistic Lifestyle Change - Video

Healing Energy
Learn about Healing Energy from Kristine Soly MD, board certified in Internal Medicine, Cardiology, and Holistic Medicine. Learn more at http://www.drsoly.comFrom:Kristine SolyViews:0 0ratingsTime:04:23More inEducation

Go here to see the original:

Healing Energy - Video

Changing the World: Building A Clinic, Bridging Worlds - UC Education Abroad
While studying abroad in Ghana, EAP participant Jeremy Kirshbaum launched an effort to help residents of a remote mountain village construct a life-saving medical clinic. Through ecotourism, bead sales and benefit concerts, UC Santa Cruz students are helping residents of this mountain community acquire critical funding and health resources, while forging enduring connections across continents and cultures. Going Places: UC Education Abroad: http://www.uctv.tv Learn more about UC #39;s Education Abroad Program: eap.ucop.edu UCTV Prime: http://www.uctv.tv Series: "Going Places: UC Education Abroad" [Health and Medicine] [Education] [Show ID: 24591]From:UCTVPrimeViews:7 0ratingsTime:06:18More inEducation

Go here to read the rest:

Changing the World: Building A Clinic, Bridging Worlds - UC Education Abroad - Video

87th Annual Colloid Surface Science Symposium at UC Riverside
An invitation from Associate Professor of Chemical and Environmental Engineering Sharon Walker to attend the American Chemical Society #39;s 87th Annual Colloid Surface Science Symposium (colloids2013.ucr.edu at UC Riverside, June 23-26, 2013. Keynote speakers will be Barbara J. Finlayson-Pitts, UC Irvine, and Joanna Aizenberg, Harvard University. There will be 12 concurrent sessions in such areas as atmospheric and surface science, energy conversion and storage, medicine and drug delivery, and sensing for biomedical and environmental applications.From:BournsCollegeViews:0 0ratingsTime:02:29More inEducation

Read more:

87th Annual Colloid

Doctors are too scared to deviate from evidence-based medicine, says Max Pemberton

Read this article:

The fear of being sued is ruining modern medicine

VILLEJUIF, France--(BUSINESS WIRE)--

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc (PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

Pfizers strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the companys deep breadth of experience in the development of oncology therapeutics, strategically align the companys goals and capabilities with the mission of the WIN Consortium. As the newest member of the consortium, Pfizer will play an integral role in shaping the future achievements of this collective group on behalf of cancer patients around the world.

"Bringing the latest advances in personalized cancer medicine to the patient requires collaboration and partnerships between multiple sectors of the health sciences community, said Professor Alexander Eggermont, General Director, Institut Gustave Roussy and Vice-Chairman of WIN Consortium. Pfizer's strong commitment to the development of targeted cancer therapeutics and its breadth of expertise in oncology drug development will play a key role in accelerating the pace at which patients can benefit from advances in personalized cancer medicine. We are proud to have Pfizer as WIN's first pharmaceutical partner and believe that this collaboration will benefit cancer patients worldwide."

Pfizers advanced capabilities in the development of targeted oncology therapies will provide a breadth of insights and opportunities to the Consortium. Pfizer is actively developing a strong pipeline of oncology drugs active against a specific target or pathway, with programs in areas including oncogenic drivers / cell signaling, antibody drug conjugates, anti-angiogenesis, and cancer stem cells, metabolism, and epigenetics. As the worlds largest research-based pharmaceutical company, Pfizer is active in over 100 oncology focused clinical trials annually.

Pfizer is excited to become the first pharmaceutical company to join the WIN Consortium and to be able to contribute our expertise and resources in oncology drug development to this important collaboration, said Dr. Richard Buller, Vice President of Translational Oncology for Pfizers Oncology Business Unit. Personalized cancer care is an important part of our mission at Pfizer and this initiative provides a unique forum to collectively share insights, exchange ideas, and positively impact cancer patients.

Initiated in 2010 by the University of Texas MD Anderson Cancer Center (USA) and the Institut Gustave Roussy (France), the WIN Consortium is a global network of 25 leading organizations from the academic, pharmaceutical, biotechnology, healthcare IT, and patient advocacy sectors working to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN is a non-governmental, not-for-profit organization headquartered in Paris.

For further information, please visit http://www.winconsortium.org.

Visit link:

WIN Consortium and Pfizer Collaborate to Advance Personalized Cancer Care

HELENA - Monica Seidel of Medicine Lake claimed a $250,000 prize in the "$250,000 Extravaganza" Scratch game on Monday. Seidel picked up her winnings at Lottery headquarters in Helena on Monday. She bought her winning ticket at the Eight Ball Inn in Medicine Lake, where she also happens to work.

View post:

Medicine Lake woman scores $250K in Montana Lottery

MANILA, Philippines --- The Philippine College for the Advancement of Medicine (PCAM), which Dr. Robin Buhain Navarro represents as its president, acknowledges the need for greater acceptance of "natural medicine" among Filipinos as a viable compliment to traditional or conventional medicine.

"It's actually natural medicine, not alternative medicine," stressed Dr. Erwin Torres, spokesperson of the 500-member PCAM.

"When we say alternative (medicine), it's an entirely different thing. It could cover pagtatawas or what we call psychic healing. But it's complimentary. This involves nutrition and supplementation. We also promote healthy living, healthy lifestyle," he said.

Torres also acknowledged that their practice oftentimes becomes the last choice for patients, whereas he thinks that the treatment offered by natural medicine could help manage illnesses at the onset.

"What happens is that we become the last choice. The patient only comes to us when conventional medicine has exhausted all procedures. It should be open from start when the patient is diagnosed that he or she has an option with natural medicine.

"The management could be conventional or natural, but it should be the patient who decides which treatment he or she wants."

Still, he said that PCAM's work is focused on harmonizing natural and conventional medicine, and not the contrary.

"What I always say is let's not pit them against each other. PCAM has been trying to harmonize the two. Even if we practice natural medicine, we are not against operations or those medical procedures. What we do is just disseminate information that will serve as guide in the patients' choice of modalities."

In fact, Torres said that PCAM is currently conducting several researches of treatments in combination with conventional medicine. These include research on hyperbaric oxygen therapy and research on hydrotherapy (a natural medicine staple) to replace enema before colonoscopy.

Nutrition Is The Key

Excerpt from:

It’s Natural, Not Alternative Medicine

Socialized Medicine: 2+2=5
http://www.youtube.com/aapsonline http://www.aynrand.org Arm yourself with intellectual ammunition, fight for free market capitalism. Reject socialized medicine.From:Anita BathViews:0 0ratingsTime:02:51More inNews Politics

More here:

Socialized Medicine: 2+2=5 - Video

AMV - Medicine 720p
Editor - Elcalavero [WARNING: This video contains lots of Blood Gore!] Subscribe to Elcalavero: http://www.youtube.com dl: http://www.animemusicvideos.org http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com http://www.youtube.com **NOTE: This AMV is made with non-profit or does not represent another company. I do not own the copyrights to the "video clips" or the "music" in the video! #39;Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for #39;fair use #39; for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use #39;From:NeverEnoughEpicAMVs3Views:123 14ratingsTime:02:49More inNonprofits Activism

Continue reading here:

AMV - Medicine 720p - Video

Waterproof Mini Capsule Pill Holder Container Medicine Case
Waterproof Mini Capsule Pill Holder Container Medicine Case with Key Ring for Outdoor Travel http://www.priceangels.comFrom:TbayListViews:1 0ratingsTime:01:28More inPeople Blogs

Go here to read the rest:

Waterproof Mini Capsule Pill Holder Container Medicine Case - Video

Tim Vanstone vs Gavin Broadhead Dec 8, 2012
Tim Vanstone vs Gavin Broadhead from the Prince Albert Raiders at Medicine Hat Tigers game on Dec 8, 2012. via http://www.hockeyfights.comFrom:hockeyfightsplusViews:0 0ratingsTime:01:12More inSports

More:

Tim Vanstone vs Gavin Broadhead Dec 8, 2012 - Video